Avacopan in the treatment of ANCA-associated vasculitis

References

• Watts RA, Mahr A, Mohammad AJ, et al. Classification, epidemiology and clinical subgrouping of antineutrophil cytoplasmic antibody (ANCA) – associated vasculitis. Nephrol Dial Transplant. 2015;Suppl 1:i14–22.
   Google Scholar
• Jennette JC, Falk RJ, Bacon PA, et al. 2012 revised international Chapel Hill consensus conference nomenclature of vasculitides. Arthritis Rheum. 2013;65:1–11.
   PubMed Web of Science ®Google Scholar
• Lionaki S, Blyth ER, Hogan SL, et al. Classification of antineutrophil cytoplasmic autoantibody vasculitides: the role of antineutrophil cytoplasmic autoantibody specificity for myeloperoxidase or proteinase 2 in disease recognition and prognosis. Arthritis Rheum. 2012;64:3452–3462.
   PubMed Web of Science ®Google Scholar
• Fauci AS, Haynes BF, Katz P, et al. Wegener´s granulomatosis: prospective clinical and therapeutic experience with 85 patients for 21 years. Ann Intern Med. 1983;98:76–85.
   PubMed Web of Science ®Google Scholar
• Hoffman GS, Kerr GS, Leavitt RY, et al. Wegener granulomatosis: an analysis of 158 patients. Ann Intern Med. 1992;116:488–498.
   PubMed Web of Science ®Google Scholar
• Flossmann O, Berden A, De Groot K, European Vasculitis Study Group; et al. Long-term patient survival in ANCA-associated vasculitis. Ann Rheum Dis. 2011;70:488–494.
   PubMed Web of Science ®Google Scholar
• Mohammad AJ, Segelmark M. A population-based study showing better renal prognosis for proteinase 3 antineutrophil cytoplasmic antibody (ANCA)-associated nephritis versus myeloperoxidase ANCA-associated nephritis. J Rheumatol. 2014;41:1366–1373.
   PubMed Web of Science ®Google Scholar
• Stone JH, Merkel PA, Spiera R, RAVA-ITN Research Group; et al. Rituximab versus cyclophosphamide for ANCA-associated vasculitis. N Engl J Med. 2010;363:221–232.
   PubMed Web of Science ®Google Scholar
• Van Daalen EE, Rizzo R, Kronbichler A, et al. Effect of rituximab on malignancy risk in patients with ANCA-associated vasculitis. Ann Rheum Dis. 2017;76:1064–1069.
   PubMed Web of Science ®Google Scholar
• McGregor JG, Hogan SL, Hu Y, et al. Glucocorticoids and relapse and infection rates in anti-neutrophil cytoplasmic antibody disease. Clin J Am Soc Nephrol. 2012;7:240–247.
   PubMed Web of Science ®Google Scholar
• Robson J, Doll H, Suppiah R, et al. Glucocorticoid treatment and damage in the anti-neutrophil cytoplasm antibody-associated vasculitides: long-term data from the European Vasculitis Study Group trials. Rheumatology (Oxford). 2015;54:471–481.
   PubMed Web of Science ®Google Scholar
• Bekker P, Dairaghi D, Seitz L, et al. Characterization of pharmacologic and pharmacokinetic properties of CCX168, a potent and selective orally administered complement 5a receptor inhibitor, based on preclinical evaluation and randomized phase 1 clinical study. PLoS One. 2016;11:e0164646.
   PubMed Web of Science ®Google Scholar
• Xiao H, Schreiber A, Heeringa P, et al. Alternative complement pathway in the pathogenesis of disease mediated by anti-neutrophil cytoplasmic autoantibodies. Am J Pathol. 2007;170:52–64.
   PubMed Web of Science ®Google Scholar
• Schreiber A, Xiao H, Jennette JC, et al. C5a receptor mediates neutrophil activation and ANCA-induced glomerulonephritis. J Am Soc Nephrol. 2009;20:289–298.
   PubMed Web of Science ®Google Scholar
• Schreiber A, Rousselle A, Becker JU, et al. Necroptosis controls NET generation and mediates complement activation, endothelial damage and autoimmune vasculitis. Proc Natl Acad Sci USA. 2017;114:E9618–E9625.
   PubMed Web of Science ®Google Scholar
• Gou SJ, Yuan J, Chen M, et al. Circulating complement activation in patients with anti-neutrophil cytoplasmic antibody-associated vasculitis. Kidney Int. 2013;83:129–137.
   PubMed Web of Science ®Google Scholar
• Gou SJ, Yuan J, Wang C, et al. Alternative complement pathway activation products in urine and kidneys of patients with ANCA-associated GN. Clin J Am Soc Nephrol. 2013;8:1884–1891.
   PubMed Web of Science ®Google Scholar
• Kallenberg CG, Heeringa P. Complement is crucial in the pathogenesis of ANCA-associated vasculitis. Kidney Int. 2013;83:16–18.
   PubMed Web of Science ®Google Scholar
• Manenti L, Urban ML, Maritati F, et al. Complement blockade in ANCA-associated vasculitis: an index case, current concepts and future perspectives. Intern Emerg Med. 2017;12:727–731.
   PubMed Web of Science ®Google Scholar
• Horiuchi T, Tsukamoto H. Complement-targeted therapy: development of C5- and C5a-targeted inhibition. Inflamm Regen. 2016;36:11.
   PubMedGoogle Scholar
• Jayne DRW, Bruchfeld AN, Harper L, CLEAR Study Group; et al. Randomized trial of C5a receptor inhibitor avacopan in ANCA-associated vasculitis. J Am Soc Nephrol. 2017;28:2756–2767.
   PubMed Web of Science ®Google Scholar
• Stangou M, Asimaki A, Bamichas G, et al. Factors influencing patient survival and renal function outcome in pulmonary-renal syndrome associated with ANCA(+) vasculitis: a single-center experience. J Nephrol. 2005;18:35–44.
   PubMed Web of Science ®Google Scholar
• Tam FW, Sanders JS, George A, et al. Urinary monocyte chemoattractant protein-1 (MCP-1) is a marker of active renal vasculitis. Nephrol Dial Transplant. 2004;19:2761–2768.
   PubMed Web of Science ®Google Scholar
• Ohlsson S, Bakoush O, Tencer J, et al. Monocyte chemoattractant protein 1 is a prognostic marker in ANCA-associated small vessel vasculitis. Mediators Inflamm. 2009;584916. DOI:10.1155/2009/584916.
   PubMed Web of Science ®Google Scholar
• Merkel PA, Niles J, Jimenez R, et al. A randomized clinical trial of CCX168, an orally administered C5aR inhibitor for treatment of patients with ANCA-associated vasculitis (abstract). Arthritis Rheumatol. 2016;68(suppl 10). http://acrabastracts.org/abstract/a-randomized-clinical-trial-of-ccx168-an-orally-administered-c5ar-inhibitor-for-treatment-of-patients-with-anca-associated-vasculitis.
   Google Scholar